This study is not yet accepting patients
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Clinical Trials Information
- ID
- NCT06891066
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 150 study participants
- Last Updated